MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Corcept Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

70.87 -3.02

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

70.52

Max

73.22

Schlüsselkennzahlen

By Trading Economics

Einkommen

-9.8M

21M

Verkäufe

-25M

157M

KGV

Branchendurchschnitt

63.278

39.857

EPS

0.169

Gewinnspanne

13.069

Angestellte

500

EBITDA

-22M

3.4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+90.6% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

28. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.4M

7.7B

Vorheriger Eröffnungskurs

73.89

Vorheriger Schlusskurs

70.87

Nachrichtenstimmung

By Acuity

56%

44%

313 / 376 Ranking in Healthcare

Corcept Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Juli 2025, 21:01 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 20:46 UTC

Ergebnisse

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. Juli 2025, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 20:36 UTC

Ergebnisse

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. Juli 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. Juli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. Juli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. Juli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. Juli 2025, 18:24 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. Juli 2025, 18:19 UTC

Ergebnisse

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. Juli 2025, 18:11 UTC

Akquisitionen, Fusionen, Übernahmen

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. Juli 2025, 18:11 UTC

Ergebnisse

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. Juli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. Juli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. Juli 2025, 16:28 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 16:04 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. Juli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. Juli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. Juli 2025, 15:47 UTC

Market Talk
Ergebnisse

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer-Vergleich

Kursveränderung

Corcept Therapeutics Inc Prognose

Kursziel

By TipRanks

90.6% Vorteil

12-Monats-Prognose

Durchschnitt 139.33 USD  90.6%

Hoch 145 USD

Tief 131 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corcept Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Stimmung

By Acuity

313 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.